Ladies and gentlemen, welcome to the Coloplast Interim Financial Statement for Q1 2025-'26 Conference Call. I am [indiscernible] chorus Call operator. [Operator Instructions] the conference has been ...

Coloplast delivered Q1 organic growth of 6% and EBIT growth 1 in constant currencies of 3%. Reported revenue in DKK grew 0%, reflecting 4%-points negative impact from currencies. Return on invested ...

Ladies and gentlemen, welcome to the Coloplast financial statement for the full year 2024/2025 and Annual Report 2024-2025 Conference Call. I am Sandra, the Chorus Call operator. [Operator ...

Coloplast interim CEO Lars Rasmussen has today informed the Coloplast Board of Directors that he will not stand for re-election as board member at the upcoming annual general meeting on December 4, ...

This announcement is available in a Danish and an English-language version. In the event of discrepancies, the English version shall prevail. Coloplast was founded on passion, ambition, and commitment ...

The Coloplast Board of Directors are making changes to the Executive Leadership Team (ELT) to support the successful execution of the new Coloplast Group strategy. Over the last couple of months, ...

On Monday, Barclays (LON:BARC) analysts downgraded Coloplast (CSE:COLOb) A/S (COLOB:DC) (OTC: CLPBY) stock rating from Overweight to Equalweight and reduced the price target to DKK750.00 from DKK1,010 ...

(Bloomberg) — Coloplast A/S fired its chief executive officer to restore investor confidence after the medical equipment maker failed to deliver sufficient shareholder returns. That’s according to ...

Coloplast CEO Kristian Villumsen steps down from his CEO position as of today. The Board of Directors has asked Lars Rasmussen to step in as interim CEO. As the company is entering into a new strategy ...

Coloplast (CSE:COLOb) has been upgraded to an "outperform" rating by RBC Capital Markets, with analysts citing a positive risk-reward balance and a price target increase to DKK 940 per share from DKK ...

On Wednesday, UBS analyst changed the rating for Coloplast (CSE:COLOb) A/S (COLOB:DC) (OTC: CLPBY) from Sell to Neutral, maintaining a price target of DKK858.00. The revision follows a reassessment of ...